Document -
Leading hematology journal publishes pivotal Eloctate data that demonstrated efficacy and safety of investigational long-lasting therapy for hemophilia A
Phase 3 Study Showed Potential for Once- or Twice-Weekly Prophylactic Dosing Regimens
-
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format: .pdf